• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum.

作者信息

Noureddin Mazen, Chan Jean L, Barradas Katherine, Dimick-Santos Lara, Schabel Elmer, Omokaro Stephanie O, Anania Frank A, Myers Robert P, Miller Veronica, Sanyal Arun J, Chalasani Naga

机构信息

Cedars Sinai Medical Center, Los Angeles, California.

Conatus Pharmaceuticals, San Diego, California.

出版信息

Gastroenterology. 2020 Aug;159(2):422-427.e1. doi: 10.1053/j.gastro.2020.04.039. Epub 2020 Apr 27.

DOI:10.1053/j.gastro.2020.04.039
PMID:32353369
Abstract
摘要

相似文献

1
Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum.将非酒精性脂肪性肝炎归因于临床试验合格性的肝硬化病因：多方利益相关者肝脏论坛的建议
Gastroenterology. 2020 Aug;159(2):422-427.e1. doi: 10.1053/j.gastro.2020.04.039. Epub 2020 Apr 27.
2
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum.定义非酒精性脂肪性肝炎治疗试验终点的改善：来自肝脏论坛的建议。
Hepatology. 2019 Nov;70(5):1841-1855. doi: 10.1002/hep.30672.
3
Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.非酒精性脂肪性肝炎：更广泛背景下的组织病理学基础
Surg Pathol Clin. 2018 Jun;11(2):267-285. doi: 10.1016/j.path.2018.02.013.
4
Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎的管理和治疗建议。
Transplantation. 2019 Jan;103(1):28-38. doi: 10.1097/TP.0000000000002483.
5
Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.非酒精性脂肪性肝炎临床试验的基线参数：肝脏论坛的建议
Gastroenterology. 2017 Sep;153(3):621-625.e7. doi: 10.1053/j.gastro.2017.07.024. Epub 2017 Jul 27.
6
[Machanism and intervention of nonalcoholic steatohepatitis-associated fibrosis].[非酒精性脂肪性肝炎相关纤维化的机制与干预]
Zhonghua Gan Zang Bing Za Zhi. 2019 Jun 20;27(6):415-419. doi: 10.3760/cma.j.issn.1007-3418.2019.06.005.
7
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.肝硬化的挑战与管理：非酒精性脂肪性肝病和非酒精性脂肪性肝炎所致肝硬化患者治疗中的实际问题
Dig Dis. 2015;33(4):598-607. doi: 10.1159/000375353. Epub 2015 Jul 6.
8
Pathophysiology guided treatment of nonalcoholic steatohepatitis.基于病理生理学的非酒精性脂肪性肝炎治疗策略
J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2(Suppl 2):58-64. doi: 10.1111/j.1440-1746.2011.07018.x.
9
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.共识指南：成人慢性病毒性肝炎和乙型、丙型肝炎及非酒精性脂肪性肝炎相关性肝硬化患者临床试验中疑似急性药物性肝损伤的检测、评估和管理的最佳实践。
Drug Saf. 2021 Feb;44(2):133-165. doi: 10.1007/s40264-020-01014-2. Epub 2020 Nov 3.
10
Evolving Management Strategies for Nonalcoholic Fatty Liver Disease-Targeting Primary Care Physicians.非酒精性脂肪性肝病不断发展的管理策略——以基层医疗医生为目标群体
Diabetes Technol Ther. 2019 Nov;21(11):611-618. doi: 10.1089/dia.2019.0158. Epub 2019 Jul 29.

引用本文的文献

1
Hepatocellular Carcinoma Surveillance and Survival in a Contemporary Asia-Pacific Cohort.当代亚太队列中的肝细胞癌监测与生存情况
JAMA Netw Open. 2025 Jul 1;8(7):e2520294. doi: 10.1001/jamanetworkopen.2025.20294.
2
Impact of catheter tip to hepatic vein ostium distance on the validity and prognostication of hepatic venous pressure gradient in cirrhosis.肝静脉开口至导管尖端距离对肝硬化肝静脉压力梯度测量准确性和预后评估的影响。
Sci Rep. 2023 Oct 9;13(1):16980. doi: 10.1038/s41598-023-44016-7.
3
Global epidemiology of cirrhosis - aetiology, trends and predictions.
全球肝硬化的流行病学：病因、趋势和预测。
Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):388-398. doi: 10.1038/s41575-023-00759-2. Epub 2023 Mar 28.
4
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.机器学习肝组织学评分与非酒精性脂肪性肝炎肝硬化门静脉高压评估相关。
Aliment Pharmacol Ther. 2023 Feb;57(4):409-417. doi: 10.1111/apt.17363. Epub 2023 Jan 17.
5
Magnetic Resonance Elastography as a Predictor of Response to Therapy in Patients With Nonalcoholic Steatohepatitis.磁共振弹性成像作为非酒精性脂肪性肝炎患者治疗反应的预测指标
Gastroenterol Hepatol (N Y). 2021 Oct;17(10):488-490.
6
Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis.非酒精性脂肪性肝炎肝硬化未来临床试验的结局和潜在替代标志物。
Liver Int. 2021 Sep;41(9):1999-2008. doi: 10.1111/liv.15013. Epub 2021 Jul 21.
7
Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors.非酒精性脂肪性肝病患者住院与全因死亡率增加相关，与心血管危险因素无关。
PLoS One. 2020 Oct 27;15(10):e0241357. doi: 10.1371/journal.pone.0241357. eCollection 2020.